Total Payments
$1.2M
2024 Payments
$67,498
Companies
42
Transactions
952
Payment Breakdown by Category
Consulting$667,635 (55.9%)
Research$340,927 (28.5%)
Travel$99,148 (8.3%)
Other$73,578 (6.2%)
Food & Beverage$12,705 (1.1%)
Education$1,104 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $667,635 | 230 | 55.9% |
| Unspecified | $340,927 | 32 | 28.5% |
| Travel and Lodging | $99,148 | 286 | 8.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $73,578 | 39 | 6.2% |
| Food and Beverage | $12,705 | 363 | 1.1% |
| Education | $1,104 | 2 | 0.1% |
Payments by Type
General
$854,169
920 transactions
Research
$340,927
32 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bausch Health US, LLC | $296,800 | 3 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $100,260 | 65 | $0 (2024) |
| ABBVIE INC. | $90,088 | 152 | $0 (2024) |
| UCB SA | $62,627 | 36 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $59,931 | 74 | $0 (2024) |
| Boehringer Ingelheim International GmbH | $54,387 | 66 | $0 (2024) |
| Janssen Biotech, Inc. | $50,616 | 81 | $0 (2024) |
| Janssen Global Services, LLC | $48,077 | 45 | $0 (2024) |
| Eli Lilly and Company | $45,930 | 31 | $0 (2023) |
| Biogen, Inc. | $38,234 | 33 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $67,498 | 133 | Boehringer Ingelheim International GmbH ($14,405) |
| 2023 | $121,238 | 102 | E.R. Squibb & Sons, L.L.C. ($46,374) |
| 2022 | $113,272 | 107 | Janssen Global Services, LLC ($21,847) |
| 2021 | $106,895 | 63 | Novartis Pharmaceuticals Corporation ($15,833) |
| 2020 | $69,807 | 41 | Boehringer Ingelheim International GmbH ($8,305) |
| 2019 | $427,095 | 172 | Bausch Health US, LLC ($296,800) |
| 2018 | $194,236 | 210 | Allergan Inc. ($30,800) |
| 2017 | $95,055 | 124 | Novartis Pharmaceuticals Corporation ($14,909) |
All Payment Transactions
952 individual payment records from CMS Open Payments — Page 1 of 39
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | Boehringer Ingelheim International GmbH | SPEVIGO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $232.67 | General |
| Category: IMMUNOLOGY | ||||||
| 12/30/2024 | Boehringer Ingelheim International GmbH | SPEVIGO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $8.33 | General |
| Category: IMMUNOLOGY | ||||||
| 12/13/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Food and Beverage | In-kind items and services | $25.00 | General |
| 12/03/2024 | Boehringer Ingelheim International GmbH | SPEVIGO (Drug) | Travel and Lodging | In-kind items and services | $0.84 | General |
| Category: IMMUNOLOGY | ||||||
| 11/11/2024 | Janssen Global Services, LLC | TREMFYA (Drug) | Consulting Fee | Cash or cash equivalent | $1,838.98 | General |
| Category: Immunology | ||||||
| 11/11/2024 | Janssen Global Services, LLC | TREMFYA (Drug) | Travel and Lodging | Cash or cash equivalent | $507.15 | General |
| Category: Immunology | ||||||
| 11/11/2024 | Janssen Global Services, LLC | TREMFYA (Drug) | Travel and Lodging | Cash or cash equivalent | $35.24 | General |
| Category: Immunology | ||||||
| 11/04/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $2,266.50 | General |
| 11/04/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $2,091.90 | General |
| 11/04/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | In-kind items and services | $625.05 | General |
| 11/04/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $576.90 | General |
| 11/04/2024 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $476.56 | General |
| 11/04/2024 | Boehringer Ingelheim International GmbH | SPEVIGO (Drug) | Consulting Fee | Cash or cash equivalent | $283.92 | General |
| Category: IMMUNOLOGY | ||||||
| 11/04/2024 | Boehringer Ingelheim International GmbH | SPEVIGO (Drug) | Travel and Lodging | In-kind items and services | $78.30 | General |
| Category: IMMUNOLOGY | ||||||
| 11/04/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | In-kind items and services | $43.43 | General |
| 11/04/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $40.08 | General |
| 11/04/2024 | Boehringer Ingelheim International GmbH | SPEVIGO (Drug) | Travel and Lodging | In-kind items and services | $5.44 | General |
| Category: IMMUNOLOGY | ||||||
| 11/03/2024 | Boehringer Ingelheim International GmbH | SPEVIGO (Drug) | Food and Beverage | In-kind items and services | $2.20 | General |
| Category: IMMUNOLOGY | ||||||
| 11/03/2024 | Boehringer Ingelheim International GmbH | SPEVIGO (Drug) | Food and Beverage | In-kind items and services | $1.06 | General |
| Category: IMMUNOLOGY | ||||||
| 11/01/2024 | Janssen Scientific Affairs, LLC | TREMFYA (Drug) | Consulting Fee | Cash or cash equivalent | $1,100.00 | General |
| Category: Immunology | ||||||
| 10/30/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | SPEVIGO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $6,301.50 | General |
| Category: IMMUNOLOGY | ||||||
| 10/25/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $91.75 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/25/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $30.00 | General |
| Category: Immunology | ||||||
| 10/23/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| 10/03/2024 | Boehringer Ingelheim International GmbH | SPEVIGO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $1,208.72 | General |
| Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| 2018-4904-Krueger | Bausch Health US, LLC | $222,600 | 2 |
| 2018-4904 Krueger | Bausch Health US, LLC | $74,200 | 1 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $10,779 | 1 |
| INFLAMIMMUNO CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $7,670 | 4 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $3,683 | 5 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY INVESTIGATING THE EFFICACY, SAFETY, SERUM CONCENTRATION AND BIOMARKER PROFILE OF DUPILUMAB ADMINISTERED TO ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $2,702 | 2 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $2,664 | 5 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $2,663 | 2 |
| IL-36 Clinical Development Program | Regeneron Pharmaceuticals, Inc. | $1,617 | 1 |
| A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Investigating the Efficacy, Safety, Serum Concentration and Biomarker Profile of Dupilumab Administered to Adult Patients With Mode | SANOFI-AVENTIS U.S. LLC | $985.11 | 2 |
| DUPIXENT CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $938.19 | 2 |
| CC-10004-PSOR-008 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects with Moderate to Severe Plaque Psoriasis | Celgene Corporation | $578.00 | 1 |
| AN EXPLORATORY RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PARALLEL GROUP MULTICENTER STUDY TO EXPLORE THE MODULATION OF INFLAMMATION IN THE SKIN CUTANEOUS ADIPOSE TISSUE AND BLOOD ENDOTHELIAL CELL INTERFACE BY COSENTYX SECUKINUMAB VERSUS PLACEBO IN MODERATE TO SEVERE PLAQUE PSORIASIS PATIENTS ADIPSO | Novartis Pharmaceuticals Corporation | $259.00 | 1 |
About James Krueger, MD, PHD
James Krueger, MD, PHD is a Dermatology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/27/2010. The National Provider Identifier (NPI) number assigned to this provider is 1821307703.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, James Krueger, MD, PHD has received a total of $1.2M in payments from pharmaceutical and medical device companies, with $67,498 received in 2024. These payments were reported across 952 transactions from 42 companies. The most common payment nature is "Consulting Fee" ($667,635).
Ad
Practice Information
- Specialty Dermatology
- Location New York, NY
- Active Since 09/27/2010
- Last Updated 09/27/2010
- Taxonomy Code 207N00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1821307703
Products in Payments
- SILIQ (Drug) $296,800
- TREMFYA (Drug) $88,380
- COSENTYX (Biological) $55,519
- Enbrel (Biological) $27,211
- TYSABRI (Biological) $26,401
- DUPIXENT (Drug) $25,452
- SPEVIGO (Drug) $16,068
- Tremfya (Drug) $14,216
- TALTZ (Drug) $12,127
- AIN457F (Biological) $9,652
- Skyrizi (Biological) $9,446
- ZINBRYTA (Biological) $9,253
- NO PRODUCT DISCUSSED (Drug) $7,995
- Sotyktu (Drug) $7,390
- bimekuzimab (Drug) $6,637
- Parsabiv (Biological) $5,200
- TARPEYO (Drug) $5,000
- XELJANZ (Drug) $3,900
- Otezla (Drug) $3,691
- Humira (Biological) $3,250
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in New York
David Cohen, M.d, M.D
Dermatology — Payments: $3.1M
Dermatology $3.1M
Dr. Amy Wechsler, M.d, M.D
Dermatology — Payments: $2.8M
Dermatology $2.8M
Dr. Alexandra Golant, M.d, M.D
Dermatology — Payments: $2.7M
Dermatology $2.7M
Emma Guttman, Md, MD
Dermatology — Payments: $2.2M
Dermatology $2.2M
Dr. Joshua Zeichner, Md, MD
Dermatology — Payments: $2.1M
Dermatology $2.1M
Dr. Mark Lebwohl
Dermatology — Payments: $2.0M
Dermatology $2.0M